SynthesisMolecular biology reports2025
Epigenetic silencing of the tumor suppressor TIMP-3 gene in upstream CpG islands in thyroid neoplasms: a cross-sectional study with systematic review.
Synthesis in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in understanding thyroid cancer pathogenesis, the specific epigenetic mechanisms driving malignant transformation remain incompletely characterized. While genetic variations have been well documented, the role of DNA methylation, particularly involving tumor suppressor genes, represents a critical knowledge gap. This resaerch aimed to evaluate the methylation status of the tissue inhibitor of metalloproteinase 3 (TIMP-3) promoter across 15 CpG sites in papillary and follicular thyroid carcinomas (PTC and FTC) compared to benign thyroid lesions, and to contextualize these findings through a review of previous studies on TIMP-3 promoter methylation.
methodsThyroid specimens from 64 patients were analyzed, including 28 with PTC, 9 with FTC, and 27 with benign thyroid nodules. TIMP-3 expression was evaluated by qRT-PCR, and promoter methylation status was assessed using bisulfite sequencing PCR. For systematic review, a comprehensive literature search was conducted using specific terms related to "thyroid neoplasms," "DNA methylation," and "TIMP-3" across Web of Science, Scopus, and PubMed/MEDLINE databases.
resultsTIMP-3 mRNA levels were decreased in FTC and PTC tumor tissues compared to adjacent normal thyroid tissue (P = 0.02 and P = 0.03). FTC tissues showed reduced TIMP-3 expression compared to benign nodule lesions (P = 0.04). The highest methylation in PTC samples occurred at the 8th, 6th, and 5th CpG sites, while in FTC samples, it was at the 15th, 9th, 2nd, 12th, and 14th CpG sites. Significant hypermethylation was observed in the TIMP-3 promoter in both tumor tissues in comparison to adjacent normal thyroid tissue and benign nodule lesions (P < 0.05). There was a significant correlation between expression and total hypermethylation status of PTC and FTC tissues (P < 0.05). A literature search identified five relevant studies.
conclusionChanges in the methylation pattern of the TIMP-3 promoter could help distinguish between benign and malignant thyroid nodules. These changes could be explored as targets for demethylation interventions, potentially opening new avenues for treatments aimed at restoring normal methylation patterns and influencing thyroid nodule behavior.
Indexed as
Identifiers
40593331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.